Search - tctmd.com

Displaying 421 - 440 of 1099

Sort: Relevancy | Date

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Industry News

EDWARDS INTUITY Elite Rapid Deployment Valve Receives FDA Approval

August 15, 2016

News Daily News

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Yael L. Maxwell

August 15, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Industry News

Edwards Receives Approval For SAPIEN 3 Heart Valve In Canada

July 28, 2016

News Daily News

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

L.A. McKeown

July 27, 2016

News Daily News

简单风险评分系统预测 TAVR 后死亡率

Michael O'Riordan

July 25, 2016

News Daily News

Un Sistema Simple de Puntuación del Riesgo Predice la Mortalidad Post-TAVR

Michael O'Riordan

July 25, 2016

News Daily News

Minimally Invasive Mitral Valve Chordal Replacement Procedure Promising, but It’s Still Early Days

Shelley Wood

July 20, 2016

News Daily News

La Intervención de Sustitución Mínimamente Invasiva de las Cuerdas de la Válvula Mitral es Prometedora pero está en su Infancia

Shelley Wood

July 20, 2016

News Daily News

Combining Off-Pump CABG and Transaortic TAVR May Be an Option in Some Cases

Todd Neale

July 14, 2016

News Daily News

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

Yael L. Maxwell

July 12, 2016

News Daily News

MAC 全球登记首次发表的报告强调了经导管二尖瓣置换的风险和机遇

Shelley Wood

July 11, 2016

News Daily News

First Published Report From MAC Global Registry Highlights Risks, Opportunities for Transcatheter Mitral Valve Replacement

Shelley Wood

July 11, 2016

News Daily News

El 1er Informe Publicado del Registro MAC Global Refleja los Riesgos y Oportunidades de la Sustitución de la Válvula Mitral Transcatéter

Shelley Wood

July 11, 2016

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

July 11, 2016

News Daily News

TAVR 可用于治疗二尖瓣主动脉瓣狭窄，但与永久性起搏器植入率更高相关联

Michael O'Riordan

July 05, 2016

News Daily News

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

Michael O'Riordan

July 05, 2016

News Daily News

La Intervención TAVR para el Manejo de la Estenosis de la Válvula Aórtica Bicúspide es Viable pero se asocia a un Índice Más Alto de Implantación de Marcapasos Permanente

Michael O'Riordan

July 05, 2016

News Daily News

La Estenosis Aórtica Persistente de Bajo Flujo Post-TAVR se asocia a una Mortalidad Más Alta al cabo de 1 Año

Michael O'Riordan

June 23, 2016

Advertisement

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

EDWARDS INTUITY Elite Rapid Deployment Valve Receives FDA Approval

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Edwards Receives Approval For SAPIEN 3 Heart Valve In Canada

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

简单风险评分系统预测 TAVR 后死亡率

Un Sistema Simple de Puntuación del Riesgo Predice la Mortalidad Post-TAVR

Minimally Invasive Mitral Valve Chordal Replacement Procedure Promising, but It’s Still Early Days

La Intervención de Sustitución Mínimamente Invasiva de las Cuerdas de la Válvula Mitral es Prometedora pero está en su Infancia

Combining Off-Pump CABG and Transaortic TAVR May Be an Option in Some Cases

Sapien 3: Results for High-Risk, Inoperable TAVR Patients Now in Print

MAC 全球登记首次发表的报告强调了经导管二尖瓣置换的风险和机遇

First Published Report From MAC Global Registry Highlights Risks, Opportunities for Transcatheter Mitral Valve Replacement

El 1er Informe Publicado del Registro MAC Global Refleja los Riesgos y Oportunidades de la Sustitución de la Válvula Mitral Transcatéter

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

TAVR 可用于治疗二尖瓣主动脉瓣狭窄，但与永久性起搏器植入率更高相关联

TAVR for Bicuspid Aortic Valve Stenosis Feasible, but Associated With Higher Rate of Permanent Pacemaker Implantation

La Intervención TAVR para el Manejo de la Estenosis de la Válvula Aórtica Bicúspide es Viable pero se asocia a un Índice Más Alto de Implantación de Marcapasos Permanente

La Estenosis Aórtica Persistente de Bajo Flujo Post-TAVR se asocia a una Mortalidad Más Alta al cabo de 1 Año

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content